Search for: "GENENTECH, INC." Results 281 - 300 of 469
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
24 May 2021, 7:34 am by Deb Givens
The plaintiffs have accused Ranbaxy of delaying the launch of generic versions of Novartis AG’s high blood pressure drug Diovan, Pfizer Inc’s acid reflux drug Nexium and Genentech Inc’s antiviral drug Valcyte. [read post]
28 Apr 2017, 9:56 am by Miquel Montañá
Genentech Inc.), industrial applicability (HGS v. [read post]
26 Nov 2013, 1:29 am
On that hypothesis, it would have been difficult to defend the guidance given by the Court of Appeal in Glaxo Group Ltd v Genentech Inc [2008] Bus LR 888 to the effect that the English court should normally refuse a stay of its own proceedings if it would be likely to resolve the question of validity significantly earlier. [read post]
20 Aug 2013, 8:01 am
Currently, the guidance (given in Glaxo Group Ltd v Genentech Inc [2008] Bus LR 888) is that a stay should be granted, unless it appears that "the evidence is that some commercial certainty would be achieved at a considerably earlier date in the case of the UK proceedings than in the EPO". [read post]
14 Mar 2010, 8:18 am by Lawrence B. Ebert
Genentech," which includes the text:This case arises out of a 1976 patent agreement (the agreement) that governs the right of respondent City of Hope National Medical Center (City of Hope) to receive royalties from appellant Genentech, Inc. [read post]
In undoubtedly one of the most important decisions of the year so far, on 24 August 2021, the English Court of Appeal handed down its judgment in FibroGen v Akebia (FibroGen Inc v Akebia Therapeutics Inc [2021] EWCA Civ 1279), partially allowing FibroGen’s appeal, and so finding one of the ‘Family A’ patents, EP 823, valid and infringed. [read post]
26 Feb 2016, 1:21 pm by Gene Quinn
Genentech, Inc., 549 U.S. 118 (2007), decided 8-1 with only Justice Thomas dissenting: the Court decided that the case or controversy requirement of the Constitution did not require a licensee to breach a license agreement in order to challenge the validity of a patent. [read post]
14 Mar 2016, 3:23 am
Hoffmann-La Roche AG and Genentech Inc. | Design v Copyright in Italy | Unitary patent and double patenting | Regeneron Pharmaceuticals Inc v Kymab Ltd & Anor | IKEA in Indonesia | Eli Lilly v Janssen Sciences. [read post]
23 Feb 2016, 1:53 am
Hoffmann-La Roche AG and Genentech Inc. [read post]
7 Mar 2016, 1:55 am
Hoffmann-La Roche AG and Genentech Inc. | Design v Copyright in Italy | Unitary patent and double patenting | Regeneron Pharmaceuticals Inc v Kymab Ltd & Anor | IKEA in Indonesia | Eli Lilly v Janssen Sciences.Never too late 83 [week ending on Sunday 14 February] – Indigenous IP | Arnold J's latest judgment flags down the iconic London black cab | Life of a national/EU trade mark ... in a map | A comprehensive… [read post]
8 Mar 2011, 6:33 pm by Dennis Crouch
Genentech, Inc., 549 U.S. 118 (2007) (holding that declaratory judgment jurisdiction may exist even if the patent holder could not have sued for infringement and that the apprehension that patentee will sue for infringement is not a necessary element for Article III jurisdiction); Bilski v. [read post]
18 Jan 2014, 4:57 am by Dennis Crouch
BAE Systems: 8,576,108 (active expendable decoy to fool enemy missiles); Children's Medical Center: 8,597,910 (DNA encoding Von Willebrand Factor Proteins); Colgate-Palmolive: 8,535,730 (tarter control toothpaste); Genentech, Inc.: 8,357,513; 8,399,250; 8,557,768 (genes and methods relating to the human mpl ligand polypeptide); Institut Pasteur: 8,507,196 (A kit for determining the absence of HIV-1 RNA in a biological sample); Personalized Media Communications: 8,395,707;… [read post]
21 Aug 2008, 9:43 pm
  Following the Federal Circuit's decision in Teva Pharmaceuticals USA, Inc. v. [read post]
23 Aug 2008, 1:11 am
 Lamb of Valorem Law Group at his blog, In Search of Perfect Client Service Genentech: a company that got it right - Management consultant Cliff Mintz of BioInsights Inc. at his Bio Job Blog [read post]